H. Pylori Infection Treatment in Dallas, TX

Medically reviewed by Jaison John, MD — Board-Certified Gastroenterologist
Last updated: March 2026

What Is H. Pylori?

Helicobacter pylori (H. pylori) is a spiral-shaped, gram-negative bacterium that infects the mucus lining of the human stomach. It is one of the most common chronic bacterial infections in the world, affecting approximately 4.4 billion people globally and roughly 35% of the United States population. H. pylori is uniquely adapted to survive in the harsh, acidic environment of the stomach by producing an enzyme called urease, which converts urea into ammonia and carbon dioxide, creating a neutralized microenvironment around the bacterium that protects it from gastric acid.

Once established in the stomach, H. pylori causes chronic inflammation of the gastric mucosa (chronic gastritis) that, if left untreated, can persist for decades. This chronic inflammation is the driving force behind the most significant clinical consequences of H. pylori infection: peptic ulcer disease, gastric atrophy, intestinal metaplasia, and gastric cancer. The World Health Organization has classified H. pylori as a Group 1 (definite) carcinogen for gastric adenocarcinoma since 1994, making detection and eradication a priority in gastroenterology practice.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides expert diagnosis and evidence-based treatment for H. pylori infection for patients throughout the Dallas-Fort Worth area. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine in both internal medicine and gastroenterology, ensuring that every patient receives care aligned with the latest American College of Gastroenterology (ACG) clinical guidelines for H. pylori management.

How H. Pylori Spreads

The exact routes of H. pylori transmission are not fully understood, but the infection is believed to spread primarily through:

• Oral-oral transmission — H. pylori has been detected in saliva and dental plaque, suggesting that the bacteria can spread through mouth-to-mouth contact, shared utensils, or kissing.
• Fecal-oral transmission — The bacteria can be shed in the stool and transmitted through contaminated water or food, particularly in regions with inadequate sanitation and water treatment.
• Person-to-person contact — H. pylori infection clusters within families, suggesting that close personal contact during childhood is a significant route of transmission. Children living with an infected parent or sibling have a substantially higher risk of acquiring the infection.

H. pylori infection is most commonly acquired during childhood and, once established, persists indefinitely without treatment. In the United States, prevalence is significantly higher among Hispanic Americans, African Americans, and individuals born outside the U.S., reflecting the strong association between H. pylori infection and socioeconomic conditions during childhood.

Symptoms of H. Pylori Infection

The majority of people infected with H. pylori — approximately 80% to 85% — will never develop symptoms. The infection causes chronic gastritis in virtually all infected individuals, but only a minority progress to clinically significant disease. When symptoms do occur, they are usually related to complications of the infection, particularly peptic ulcers or dyspepsia.

Common Symptoms

• Epigastric pain or burning — A gnawing, burning, or aching pain in the upper abdomen (the area between the navel and the breastbone) is the most common symptom of H. pylori-related peptic ulcers. The pain may worsen when the stomach is empty and improve temporarily after eating or taking antacids.
• Nausea — A persistent or intermittent feeling of nausea, sometimes accompanied by loss of appetite, can be associated with H. pylori gastritis or ulcers.
• Bloating and belching — Excessive bloating, abdominal distension, and frequent belching are common complaints in patients with H. pylori-related dyspepsia.
• Early satiety — Feeling full after eating only a small amount of food may occur when H. pylori inflammation affects gastric motility or when an ulcer is present.
• Loss of appetite and unintentional weight loss — Chronic nausea, abdominal discomfort, and early satiety can lead to reduced food intake and gradual weight loss over time.

Symptoms of Complications

• Black, tarry stools (melena) — Indicates upper gastrointestinal bleeding from an ulcer. Digested blood in the stool appears dark and tarry.
• Vomiting blood (hematemesis) — Vomiting bright red blood or material that looks like coffee grounds indicates an actively bleeding ulcer and requires immediate medical attention.
• Severe, persistent abdominal pain — Sudden, severe abdominal pain may indicate a perforated ulcer, a life-threatening complication that requires emergency surgery.
• Iron deficiency anemia — Chronic, slow blood loss from an ulcer or H. pylori-related gastritis can lead to iron deficiency anemia, causing fatigue, weakness, and pallor.

Causes & Risk Factors

H. pylori infection is caused by the bacterium Helicobacter pylori, which has co-evolved with humans for tens of thousands of years. The bacterium uses several survival mechanisms to establish and maintain infection in the hostile gastric environment:

• Urease production — H. pylori produces large amounts of the enzyme urease, which breaks down urea (present in gastric juice) into ammonia and carbon dioxide. The ammonia neutralizes the surrounding gastric acid, creating a protective alkaline buffer that allows the bacterium to survive and colonize the mucus layer overlying the gastric epithelium.
• Motility — H. pylori possesses multiple flagella that allow it to swim through the thick gastric mucus layer and reach the underlying epithelial cells, where it attaches and establishes a persistent infection.
• Adhesion — Specialized adhesion proteins on the surface of H. pylori allow it to bind tightly to gastric epithelial cells, resisting clearance by the normal turnover of the mucus layer and gastric emptying.
• Virulence factors — Certain strains of H. pylori carry virulence genes (particularly cagA and vacA) that produce toxins capable of damaging the gastric epithelium, promoting inflammation, and increasing the risk of ulcers and cancer. CagA-positive strains are associated with a higher risk of gastric cancer.

Risk Factors for H. Pylori Infection

• Childhood living conditions — The strongest predictor of H. pylori infection is the socioeconomic environment during childhood. Crowded living conditions, shared sleeping quarters, limited access to clean water, and poor sanitation significantly increase the risk of acquiring the infection.
• Geographic origin — H. pylori prevalence varies dramatically by region. Infection rates exceed 70% in many parts of Africa, South America, and Asia, while prevalence in North America and Western Europe is lower (30% to 40%) and declining due to improved sanitation and living standards.
• Ethnicity — In the United States, H. pylori prevalence is higher among Hispanic Americans (approximately 60%), African Americans (approximately 50%), and Asian Americans compared to non-Hispanic white Americans (approximately 20% to 30%).
• Family clustering — Living with an infected family member, particularly an infected parent or sibling, substantially increases the risk of H. pylori acquisition.
• Age — Older adults have higher prevalence rates of H. pylori infection, reflecting both cohort effects (higher infection rates in past decades) and the cumulative risk of acquisition over a lifetime.

How H. Pylori Is Diagnosed

The ACG recommends testing for H. pylori in patients with active or past peptic ulcer disease, uninvestigated dyspepsia (in patients under age 60 without alarm features), gastric MALT lymphoma, early gastric cancer, a first-degree relative with gastric cancer, unexplained iron deficiency anemia, and idiopathic thrombocytopenic purpura (ITP). Diagnostic tests for H. pylori are divided into non-invasive and invasive (endoscopy-based) methods.

Non-Invasive Tests

• Urea breath test (UBT) — The urea breath test is a highly accurate non-invasive test for active H. pylori infection. You drink a solution containing urea labeled with carbon-13 (a non-radioactive isotope). If H. pylori is present in the stomach, its urease enzyme breaks down the labeled urea into labeled carbon dioxide, which is absorbed into the bloodstream and exhaled in the breath. A breath sample is collected and analyzed for the presence of labeled CO2. The UBT has a sensitivity and specificity exceeding 95% and is the preferred non-invasive test for both initial diagnosis and confirmation of eradication after treatment.
• Stool antigen test — A stool sample is tested for H. pylori antigens (proteins) using a monoclonal antibody-based assay. The stool antigen test is nearly as accurate as the urea breath test and is a convenient alternative, particularly for patients who cannot perform the breath test. It is also recommended for confirming eradication after treatment.
• Serology (blood test) — Blood tests that detect IgG antibodies against H. pylori indicate past or present exposure to the bacterium. However, because antibodies can persist for months to years after the infection has been eradicated, serology cannot distinguish between active and past infection. The ACG does not recommend serology for confirming eradication. Serology may be useful in certain situations, such as when PPI therapy cannot be stopped or in patients with recent antibiotic use.

Important note: Proton pump inhibitors (PPIs), bismuth-containing compounds, and antibiotics can cause false-negative results on the urea breath test and stool antigen test. PPIs should be stopped for at least 1 to 2 weeks, and bismuth and antibiotics for at least 4 weeks, before testing to ensure accuracy.

Invasive (Endoscopy-Based) Tests

• Upper endoscopy (EGD) with biopsy — During an upper endoscopy, Dr. John can take small tissue samples (biopsies) from the stomach lining for H. pylori testing. Biopsies can be evaluated using a rapid urease test (CLO test), which provides results within hours, or sent for histological examination under a microscope. Endoscopy is recommended when the patient has alarm symptoms (weight loss, bleeding, dysphagia, vomiting, anemia), when the patient is over age 60 with new dyspepsia, or when direct visualization of the stomach and duodenum is needed to evaluate for ulcers, gastritis, or malignancy.
• Culture and sensitivity testing — In patients who have failed two or more eradication attempts, biopsy specimens can be sent for bacterial culture and antibiotic susceptibility testing. This allows targeted selection of antibiotics that the patient's specific H. pylori strain is sensitive to, improving the likelihood of successful eradication.

Treatment Options

The goal of H. pylori treatment is complete eradication of the bacterium from the stomach. Successful eradication heals active peptic ulcers, prevents ulcer recurrence, reduces the risk of gastric cancer, and resolves H. pylori-related gastritis. The ACG recommends treating all patients with a confirmed H. pylori infection, regardless of whether symptoms are present.

H. pylori eradication requires a combination of two or more antibiotics plus an acid-suppressing medication, typically taken for 14 days. Using multiple antibiotics simultaneously is necessary because single-antibiotic therapy results in unacceptably high rates of treatment failure and promotes antibiotic resistance.

First-Line Regimens

• Clarithromycin-based triple therapy — A proton pump inhibitor (PPI) taken twice daily plus clarithromycin 500 mg twice daily plus amoxicillin 1,000 mg twice daily for 14 days. This regimen is recommended only in areas where clarithromycin resistance rates are below 15% and in patients who have no prior history of macrolide antibiotic exposure. In many parts of the United States, increasing clarithromycin resistance has reduced the effectiveness of this regimen.
• Bismuth quadruple therapy — A PPI twice daily plus bismuth subsalicylate four times daily plus metronidazole 250 mg four times daily plus tetracycline 500 mg four times daily for 14 days. Bismuth quadruple therapy is recommended as an alternative first-line regimen, particularly in areas with high clarithromycin resistance or in patients with a penicillin allergy (who cannot take amoxicillin). This regimen has consistently high eradication rates despite its more complex dosing schedule.
• Concomitant therapy — A PPI twice daily plus clarithromycin 500 mg twice daily plus amoxicillin 1,000 mg twice daily plus a nitroimidazole (metronidazole or tinidazole) twice daily for 14 days. By using three antibiotics simultaneously, concomitant therapy overcomes single-drug resistance and achieves higher eradication rates than standard triple therapy.

Salvage (Rescue) Regimens

When initial treatment fails to eradicate H. pylori, a different combination of antibiotics must be used for the second attempt. The ACG recommends avoiding antibiotics that were used in the failed regimen, particularly clarithromycin and levofloxacin, to minimize resistance-driven failure. Common salvage options include:

• Bismuth quadruple therapy (if not used initially)
• Levofloxacin-based triple therapy — A PPI plus levofloxacin plus amoxicillin for 14 days. Due to rising levofloxacin resistance, this regimen is used selectively and ideally guided by susceptibility testing.
• Rifabutin-based triple therapy — A PPI plus rifabutin plus amoxicillin for 14 days. This regimen is reserved for patients who have failed two or more prior attempts because H. pylori resistance to rifabutin is extremely rare.

Confirming Eradication

The ACG strongly recommends confirming successful eradication in all treated patients. A follow-up urea breath test or stool antigen test should be performed at least 4 weeks after completing antibiotic therapy and at least 1 to 2 weeks after stopping PPI therapy. Confirming eradication is critical because treatment failure rates range from 10% to 30% depending on the regimen and local resistance patterns, and persistent infection requires a different antibiotic combination.

Lifestyle Considerations During Treatment

• Complete the full 14-day course of antibiotics, even if symptoms improve before the medication is finished. Stopping early increases the risk of treatment failure and antibiotic resistance.
• Avoid alcohol during treatment, particularly when taking metronidazole, which can cause severe nausea, vomiting, and abdominal cramping when combined with alcohol (disulfiram-like reaction).
• Report any side effects to your gastroenterologist. Common side effects include nausea, diarrhea, metallic taste, and abdominal discomfort. Most side effects are mild and resolve after completing therapy.
• Take your medications as directed, including the timing relative to meals, to maximize effectiveness and minimize side effects.

Frequently Asked Questions